Results 201 to 210 of about 54,072 (297)

Deep learning approaches to predict late gadolinium enhancement and clinical outcomes in suspected cardiac sarcoidosis. [PDF]

open access: yesSarcoidosis Vasc Diffuse Lung Dis
Azoulay LD   +8 more
europepmc   +1 more source

Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo   +7 more
wiley   +1 more source

Diagnostic accuracy of late gadolinium enhancement cardiac MRI for coronary artery disease in patients with reduced left ventricular ejection fraction. [PDF]

open access: yesHeart
Desroche LM   +22 more
europepmc   +1 more source

Late Gadolinium Enhancement and Higher Risk of Arrhythmias

open access: yesJournal of the American College of Cardiology, 2011
Alter, Peter, Rupp, Heinz
openaire   +1 more source

Transendocardial injection of expanded autologous CD34+ cells after myocardial infarction: Design of the EXCELLENT trial

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1455-1463, April 2025.
Abstract Aims The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes.
Jerome Roncalli   +17 more
wiley   +1 more source

Detection of late gadolinium enhancement in patients with hypertrophic cardiomyopathy using machine learning. [PDF]

open access: yesInt J Cardiol
Akita K   +7 more
europepmc   +1 more source

Role of late gadolinium enhancement in the risk stratification of pediatric hypertrophic cardiomyopathy: based on a Chinese cohort. [PDF]

open access: yesLancet Reg Health West Pac
Chen X   +17 more
europepmc   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy